Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS by Ding, Xin-Yuan et al.
© 2012 Ding et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 1723–1735
International Journal of Nanomedicine
Pharmacokinetics, tissue distribution,  
and metabolites of a polyvinylpyrrolidone- 
coated norcantharidin chitosan nanoparticle 
formulation in rats and mice, using LC-MS/MS
Xin-Yuan Ding1
Cheng-Jiao Hong2
Yang Liu1
Zong-Lin Gu1
Kong-Lang Xing1
Ai-Jun Zhu1
Wei-Liang Chen1
Lin-Seng Shi1
Xue-Nong Zhang1
Qiang Zhang3
1Department of Pharmaceutics, 
College of Pharmaceutical Science, 
Soochow University, Suzhou,  
2Jiang Su Provincial Key Laboratory 
of Radiation Medicine and 
Protection, Suzhou, 3Department 
of Pharmaceutics, School of 
Pharmaceutical Science, Peking 
University, Beijing, People’s Republic 
of China
Correspondence: Xue-Nong Zhang 
Department of Pharmaceutics, College 
of Pharmaceutical Science, Soochow 
University, Suzhou 215123,  
People’s Republic of China 
Tel +86 512 6588 2087 
Fax +86 512 6588 2087 
Email zhangxuenong@163.com
Abstract: A novel formulation containing polyvinylpyrrolidone (PVP) K30-coated 
norcantharidin (NCTD) chitosan nanoparticles (PVP–NCTD–NPs) was prepared by ionic gelation 
between chitosan and sodium tripolyphosphate. The average particle size of the PVP–NCTD–NPs 
produced was 140.03 ± 6.23 nm; entrapment efficiency was 56.33% ± 1.41%; and drug-loading 
efficiency was 8.38% ± 0.56%. The surface morphology of NCTD nanoparticles (NPs) coated 
with PVP K30 was characterized using various analytical techniques, including X-ray diffraction 
and atomic force microscopy. NCTD and its metabolites were analyzed using a sensitive and 
specific liquid chromatography-tandem mass spectrometry method with samples from mice 
and rats. The results indicated the importance of the PVP coating in controlling the shape and 
improving the entrapment efficiency of the NPs. Pharmacokinetic profiles of the NCTD group and 
PVP–NCTD–NP group, after oral and intravenous administration in rats, revealed that relative 
bioavailabilities were 173.3% and 325.5%, respectively. The elimination half-life increased, and 
there was an obvious decrease in clearance. The tissue distribution of NCTD in mice after the 
intravenous administration of both formulations was investigated. The drug was not quantifiable 
at 6 hours in all tissues except for the liver and kidneys. The distribution of the drug in the liver 
and bile was notably improved in the PVP–NCTD–NP group. The metabolites and excretion 
properties of NCTD were investigated by analyzing rat feces and urine samples, collected after 
oral administration. A prototype drug and two metabolites were found in the feces, and seven 
metabolites in the urine. The primary elimination route of NCTD was via the urine. The quantity 
of the parent drug eliminated in the feces of the PVP–NCTD–NP group, was 32 times greater than 
that of the NCTD group, indicating that the NPs dramatically increased the reduction quantity 
from liver to bile. We conclude that PVP–NCTD–NPs are an adequate formulation for enhancing 
the absorption of NCTD, and significantly improving therapeutic effects targeting the hepatic 
system. Decarboxylation and hydroxylation were the dominant metabolic pathways for NCTD. 
Metabolites were mainly excreted into rat kidney and finally into urine.
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Introduction
Norcantharidin (NCTD), a 7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid deriva-
tive, is the demethylated analogue of cantharidin. NCTD has been reported to be very 
effective against many types of carcinoma.1–3 Recent studies have discovered that NCTD 
has a potential for use in primary hepatic carcinoma chemotherapy, administered orally 
or intravenously. However, the clinical application of NCTD has been limited by a 
serious side-effect: intense irritation of urinary organs, leading to nephrotoxicity and 
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inflammation.4,5 NCTD also has a short elimination half-life. 
Even administration in high doses is unable to maintain a high 
level of circulating activity.6,7 A number of new alternative 
dosage forms of NCTD, such as microspheres, microemul-
sions, liposomes, and nanoparticles, have been suggested 
for improving the safety and efficacy of NCTD treatment, to 
overcome the above-mentioned shortcomings.8,9
Chitosan (CS), obtained through the deacetylation of 
chitin, is an avirulent, biodegradable, and efficiently absorp-
tive cationic polymer. CS is widely used in pharmaceutical 
research, and within the pharmaceutical industry, as a car-
rier for biomedical material and drug delivery.10 It is used 
in various nanoparticles (NPs) because of its recognized 
adhesive property and its ability to enhance the penetration 
of large molecules across mucosal surfaces.11 However, 
NPs prepared from CS are unstable. To overcome this 
problem, polyvinylpyrrolidone (PVP) K30 (molecular weight 
[MW] = 50 kDa) has been used extensively as a surface-
active agent and coating material for NPs,12,13 protecting the 
drug within its framework. The extent of use of PVP K30 can 
be attributed to its excellent properties, such as biocompat-
ibility, biodegradability, and low toxicity.
Early methods for NCTD analysis in biological 
samples typically involved high-performance liquid 
chromatography (HPLC) with UV detection (HPLC-UV) 
and gas   chromatography-tandem mass spectrometry (GC/
MS). The drug could not be detected in vivo because of the 
low resolution of HPLC-UV. GC/MS was unsuitable for 
rapid high sensitivity analysis of specific compounds, due 
to its instability.14 Hence, there are very few reports on the 
pharmacokinetics and metabolism of NCTD. Other reasons 
for a lack of related studies on NCTD include its extensive 
metabolism, wide distribution, and poor absorption. All of 
these result in poor bioavailability, which directly renders 
detection of NCTD difficult. HPLC, coupled with ion trap 
mass spectrometry, has recently been found to be more than 
nine times more sensitive than HPLC-UV , and is becoming 
a useful technique for drug metabolite detection and iden-
tification.15 The ion trap can effectively produce full scan 
mass spectra, while still offering high sensitivity.16 Ion trap 
mass spectrometry also provides additional information 
for elucidating the structure of metabolites. Tandem mass 
spectrometry techniques have been proven to be more pow-
erful and reliable for studying active components, and their 
metabolism and pharmacokinetics, than other conventional 
analytical methods.17,18 In this study, a novel liquid chroma-
tography-tandem mass   spectrometry (LC/MS) method was 
developed in order to investigate the pharmacokinetics, tissue 
distribution, and metabolism of NCTD and PVP–NCTD–
NP treatments in rats and mice, after oral and intravenous 
administrations.
Materials and methods
Chemicals, reagents, and test subjects
CS (MW = 8–10 kDa; degree of deacetylation [DD] = 93.1%) 
was obtained from Jiangsu Nantong Xingcheng Biologi-
cal Product Factory, Nantong; NCTD (Lot 20100515) was 
obtained from Suzhou Surui Pharmaceutical and Chemical, 
Suzhou; Cantharidin (CTD) (Lot ZL 20091215YY) was 
obtained from Nanjing Zelang Pharmaceutical Technology, 
Nanjing; and PVP K30 (MW = 50–55 kDa) (Lot F20100414), 
was obtained from Sinopharm Chemical Reagent, Shanghai, 
People’s Republic of China. All other chemicals used were 
of analytical grade.
Sprague-Dawley (SD) rats weighing 200–250 g, and 
ICR mice, weighing 15–20 g, in equal numbers of sex, 
were supplied by the Laboratory Animals Center of the 
Medical   College of Soochow University, Suzhou. All ani-
mal experiments were performed following the guidelines 
of the National Institutes of Health for the Care of Animals, 
approved by the Experimental Animal Center, Soochow 
University, Suzhou, China.
Preparation and characterization  
of PVP–NCTD–NPs
Preparation of PVP–NCTD–NPs
PVP–NCTD–NPs were prepared using the procedure first 
reported by Calvo et al,19 which is based on the ionic gelation 
of CS with sodium tripolyphosphate (TPP) anions, with slight 
modification.20 First, 0.1 g of CS was dissolved in 50 mL of 
acetic acid solution (0.2% by volume), containing 0.04 g of 
NCTD. Second, 7.5 mL of 1.2 mg ⋅ mL−1 aqueous solution of 
TPP was added dropwise to the CS solution under magnetic 
stirring (500 rpm, 30°C), resulting in cross-linkage. Third, 
0.26 g of PVP K30 was gradually added to the solution to 
fill the interspaces in the synthesized framework and coat 
the surface of the NPs. Finally, the resulting suspension was 
filtered through a 0.45 µm pore mesh to remove insoluble 
aggregate residue, yielding a colloidal solution of PVP–
NCTD–NPs. Four factors (weight proportion of NCTD to CS, 
rotation speed, temperature, and concentration of PVP K30) 
were constantly monitored to optimize the technique for 
the preparation of PVP–NCTD–NPs. The entrapment effi-
ciency (EE), drug-loading efficiency (DL), particle size, 
and polydispersity index (PDI) of the NPs were evaluated 
using an orthogonal design method. The optimized NPs were 
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concentrated to 15 mL using a Vivaflow 50 ultrafilter with 
10 KDa polyethersulfone ultrafiltration membranes (Sartorius 
Group, Goettingen, Germany), and then freeze-dried.
Evaluation of PVP–NCTD–NPs
The freeze-dried NPs were resuspended at the original con-
centration for characterization. The particle distribution and 
zeta potential of the PVP–NCTD–NPs were measured using 
a Zetasizer NP analyzer (HPP-5001, Malvern Instruments, 
Malvern, UK). The resuspended colloid was evenly dispersed 
on a piece of slide glass to dry naturally, then visualized using 
atomic force microscopy (AFM) (MultiMode® V, Veeco, 
Plainview, NY), in contact mode. The drug yield, drug EE, 
and DL of PVP–NCTD–NPs were determined using methods 
previously described by Zhang et al.21
Dosing and sampling
Pharmacokinetics
NCTD and freeze-dried powders of PVP–NCTD–NP were 
dissolved in 0.9% (weight to volume) sodium chloride. 
Blood samples from twelve SD rats were obtained from 
both groups at specific time points after an intravenous dose 
(5 mg/kg). The samples were then centrifuged at 3500 rpm 
for 10 minutes, and the supernatant plasma was collected. 
Approximately 180 µL of plasma sample, 20 µL of CTD 
(as the internal standard), and 800 µL of methanol were 
sequentially added to a test tube, followed by centrifuga-
tion at 10,000 rpm for 10 minutes. The supernatant was 
then transferred and dried using a stream of nitrogen gas. 
After dissolution in a 100 µL, metered volume of water, 
the sample was precipitated again with 20 µL of perchloric 
acid and water (1.75:8.25, by volume). Finally, 100 µL of 
the supernatant was stored in a clean Eppendorf tube at 
4°C before analysis. Oral administration (5 mg/kg) in both 
drug groups was conducted with 12 rats. Blood samples 
were prepared for liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) analysis follow-
ing the procedure described above. Finally, drug concen-
tration was measured and drug concentration time curves 
were plotted. Pharmacokinetic parameters were computed 
using 3P97 software (Chinese Society of Mathematical 
Pharmacology, Beijing).
Tissue distribution and elimination
Tissue distribution and the elimination of total drug residues 
were determined after oral dosing with NCTD and PVP–
NCTD–NP at 5 mg/kg. Blood specimens were collected 
from the eye socket vein of mice (six mice per group) at each 
sampling time. After the mice were euthanized by cervical 
dislocation, selected organs (heart, liver, kidney, spleen, 
and lung) were dissected, briefly rinsed with normal saline, 
blotted, and weighed. Immediately, bile was collected from 
the gall bladder using a syringe. All tissues and fluids were 
pounded to homogenization, then prepared using the method 
described above.22,23 They were then analyzed to measure the 
amount of NCTD in organs. Differences in elimination rates 
of organs were plotted.
Metabolites and excretion
Twelve rats were fasted overnight before experimentation, 
held in stainless steel metabolic cages, provided with urine–
feces separators and access to water. Rat feces and urine 
were collected prior to drug administration, and for 24 hours 
after a single oral dose of NCTD or PVP–NCTD–NP. After 
feces and urine collection, the survival time of the rats was 
observed.
Approximately 1 g of sample feces from each rat was 
homogenized, dried, and then dissolved in 20 mL of a 
methanol-water mixture (2:1, by volume) via ultrasonica-
tion for 30 minutes. After centrifugation at 3000 rpm for 
12 minutes, an aliquot of 160 µL of supernatant, mixed with 
20 µL of perchloric acid and water (3:7, by volume), was 
whirled for 3 minutes, then centrifuged again for 15 minutes 
at 12,000 rpm, separating the supernatant into an Eppendorf 
tube. A 160 µL measure of urine was blended with 20 µL 
of perchloric acid and water (3:7, by volume). To prepare 
urine samples, The steps were similar to those used for 
feces samples, except that the perchloric acid and methanol 
methods of precipitation were reversed.
Samples were analysed to obtain measure of metabolite 
and drug concentration using enhanced mass spectrometry 
(EMS) and multiple reaction monitoring (MRM) modes. The 
same procedures were conducted for mouse subjects.
Analytical methods
LC-MS/MS analysis
Chromatographic analysis was carried out using an Agilent 
1100 LC system (Agilent Technologies, Palo Alto, CA), 
equipped with a degasser, quaternary pump, and   autosampler. 
Liquid chromatography was performed on a reversed phase 
column (Hypersil™ C18, [2.10 mm × 150 mm, 5 µm], 
Thermo, Scientific, Waltham, MA) at 35°C. The mobile phase 
used a methanol–water mixture (3:7, by volume), adjusted to 
pH 3.1 with formic acid, and pumped at a flow rate of 0.20 mL 
per minute, for isocratic elution. The injection volume was 
5 µL for each sample.
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Detection was carried out using a QTRAP™ 2000 triple 
quadrupole mass spectrometer (Applied Biosystems, Foster 
City, CA) with TurboIonSpray source interface. The mass 
spectrometer was operated in the negative ion mode at an 
ion source heater temperature of 350°C. Nitrogen was used 
as a nebulizer gas at 35 psi, curtain gas and high collision 
gas at 25 psi. Standard samples of NCTD and CTD were first 
scanned in EMS mode, to confirm that ions were consistent 
with the prototype molecules. Enhanced product ion mode was 
used to identify pairing of the molecules. Finally, a high mass 
resolution for NCTD and CTD ion pairs was obtained in MRM 
mode. The ramped parameters in MRM mode for NCTD and 
CTD included a −23 V declustering potential, −3.8 V entrance 
potential, −25 V collision energy, and −20 V collision cell exit 
potential. Because the ions hydrolyse easily, quantification 
was performed using the MRM mode of the transitions, from 
mass-to-charge ratio (m/z): 185.0–141.1, for NCTD, and from 
m/z 213.1–169.2, for CTD.
Calibration curves and quality control samples
An internal, matrix-matched standard calibration method 
was used for quantitative analyses. Standard stock solutions 
of NCTD and CTD were individually prepared in 0.5125 and 
0.305 mg/mL methanol, respectively. These stock solutions 
were then serially diluted with methanol to obtain working 
solutions. All stock and working solutions were stored at 
4°C until use. Calibration standards and quality control 
(QC) samples were prepared by spiking 20 µL of working 
solution, 20 µL of the internal standard (CTD, 30 µg/mL), 
and 20 µL of perchloric acid and water (3:7, by volume) 
into 160 µL of blank plasma. The resultant NCTD concen-
trations in the calibration standards were 0.1025, 0.2050, 
0.5125, 1.025, 2.050, 5.125, and 10.25 µg/mL. QC samples 
were obtained with NCTD concentrations of 0.2050, 1.025, 
and 5.125 µg/mL. Quantification was based on the ratios 
of the peak areas of each compound against those of the 
internal standards.
Results and discussion
Characteristics and evaluation  
of PVP–NCTD–NPs
PVP–NCTD–NPs were prepared under optimal conditions 
(20% NCTD to CS, by weight, with addition of 0.260 g 
PVP K30, centrifuged at 500 rpm and 30°C). All experi-
ments were repeated five times. The results showed that drug 
yield, EE, and DL of PVP–NCTD–NPs were 98.6% ± 0.2%, 
56.33% ± 1.41%, and 8.38% ± 0.56%, respectively. The NPs 
had a mean particle size of 140.03 ± 6.23 nm, and a narrow 
size distribution PDI of 0.136 ± 0.029. The zeta potential 
was 12.26 ± 1.44 mV .
X-ray diffraction was employed to investigate the immo-
bilization of PVP on NCTD NPs (Figure 1). However, the 
characteristic features seen in Figure 1a disappeared in 
Figure 1b. The reason for the difference might be that PVP 
adhered to the surface of the NPs, preventing crystallization, 
so that the characteristic features observed were only those 
of PVP.24 Figure 2 presents the difference between the NPs 
without PVP and those with PVP (PVP–NCTD–NPs). The 
PVP coating resulted in improved drug entrapment effi-
ciency and narrow particle size distribution. Figure 3 shows 
the three-dimensional structure of the NPs. They appear 
approximately elliptical, with particle size measurements 
similar to those obtained by dynamic light scattering. PVP 
plays an important role in controlling the shape and size 
distribution of particles, as well as in decreasing the degree 
of agglomeration of NCTD NPs.25
Method validation
The ionization and fragmentation patterns of NCTD and CTD 
were analyzed from mass spectra scanned from m/z 50–500, 
in negative ionization modes. The dominating ions of NCTD 
were charged molecular ions at m/z 185, in contrast to the 
charged ions at m/z 167 (specific for CTD, based on the m/z 
169–213 transition). The retention times of NCTD and CTD 
were 2.95 and 6.90 minutes, respectively.
The specificity of this method was demonstrated by 
comparing chromatograms of NCTD and CTD obtained 
from a blank sample, a spiked sample, and a sample col-
lected 30 minutes after drug administration. In the negative 
ion MRM mode, no endogenous substance in the samples 
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Figure 1 XRD pattern of NCTD and PVP–NCTD–NP nanoparticles.
Abbreviation: XRD, X-ray diffraction.
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Figure 2 AFM ichnography of NCTD-NPs and PVP–NCTD–NPs.
Notes: 1: nanoparticles without PVP; 2: nanoparticles with PVP.
Abbreviation: AFM, atomic force microscopy.
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Figure 3 AFM image of PVP–NCTD–NPs.
interfered with NCTD or CTD, and the standard curves exhib-
ited excellent linearity. The limit of detection, defined as the 
lowest concentration at which the analytical assay can reli-
ably differentiate analyte liquid chromatograph peaks from 
background levels (signal-to-noise ratio .3), was 50 ng/mL 
in the samples. The results of accuracy and precision tests 
revealed intraday and interday precisions of less than 5%, 
with accuracy within ±10%. In summary, the assay has been 
proven to be adequate and acceptable.
Pharmacokinetic studies  
of two formulations
After intravenous or oral administration of the two for-
mulations to rats from each treatment group (N = 6), 
plasma concentrations of NCTD were determined using 
LC-MS/MS. The data obtained from each group were 
averaged. Figures 4 and 5 show the mean plasma concen-
tration time curves for NCTD after intravenous and oral 
doses,   respectively. The corresponding pharmacokinetic 
parameters are presented in Table 1, which demonstrates 
that they all fit into a two-compartment open model. After 
oral dosing, plasma concentration of NCTD was very low. 
In contrast to intravenous administration, oral administra-
tion permitted the calculation of oral bioavailability, which 
was low, at only 39.3% and 68.1% for NCTD and PVP–
NCTD–NPs,   respectively. The difference might be caused by 
varying water-solubility and in vivo distribution of NCTD 
through the different administration routes. Analysis of the 
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Figure 4 Mean plasma concentration profiles of NCTD after intravenous administration of two formulations at 5 mg/kg to SD rats (N = 6).
Abbrevations: SD, Sprague-Dawley; CNCTD, concentration of NCTD; T, time.
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Figure 5 Mean plasma concentration profiles of NCTD and PVP–NCTD–NP after oral administration of 5 mg/kg to SD rats (N = 6).
Abbrevations: CNCTD, concentration of NCTD; T, time.
  PVP–NCTD–NPs group showed that that relative bioavail-
abilities, after intravenous and oral administration, were 
325.5% and 173.3% greater, respectively, than in the NCTD 
group. The absorption half-life (t1/2(a)) of the NCTD group 
was about 15 minutes, and corresponded with a previous 
report,26,27 which concluded that NCTD could only be used 
as a short-acting drug.
After intravenous administration, a long distribution half-
life (t1/2(α) = 0.73 hours) and low clearance (CL = 0.04 L/hour) 
were observed in the PVP–NCTD–NP group, compared with 
the NCTD group (t1/2(α) = 0.26 hour; CL = 0.12 L/hour). This 
suggests that the distribution and metabolism of NCTD in 
tissues and organs might have been slow. The highly effective 
absorption and sustained drug release of PVP–NCTD–NPs 
resulted in a 3–6 hour platform for the concentration of NCTD, 
in vivo, on both concentration time curves. These results dem-
onstrate that the PVP–NCTD–NP formulation can significantly 
improve drug bioavailability and sustained release effect.
Tissue distribution and elimination
After oral dosing with the two formulations, the total residue 
concentrations in tissue were highest at 1–3 hours (Figure 6), 
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Table 1 Pharmacokinetic parameters of two formulations after intravenous and oral administrations to rats
Parameter Intravenous administration (5 mg/kg) Oral administration (5 mg/kg)
NCTD PVP–NCTD–NP NCTD PVP–NCTD–NP
AUC0-t (µg ⋅ ml−1 ⋅ h) 9.79 ± 1.26 31.86 ± 4.42 3.85 ± 0.66 6.67 ± 1.00
AUC0-∞ (µg ⋅ ml−1 ⋅ h) 10.77 ± 2.34 32.90 ± 4.63 3.87 ± 0.69 6.68 ± 1.08
t1/2(a) (h) NA NA 0.56 ± 0.43 0.80 ± 0.71
t1/2(α) (h) 0.26 ± 0.06 0.73 ± 0.14 0.72 ± 0.68 0.83 ± 0.54
t1/2(β) (h) 2.63 ± 0.82 5.99 ± 1.53 5.08 ± 4.79 6.03 ± 3.06
Cmax (µg ⋅ ml−1) NA NA 1.21 ± 0.23 1.33 ± 0.31
Tmax (h) NA NA 1.50 ± 0.44 2.00 ± 0.52
MRT (h) 0.34 ± 0.10 0.93 ± 0.21 5.49 ± 4.58 6.53 ± 3.42
Vd (L ⋅ kg−1) 0.82 ± 0.45 0.62 ± 0.26 9.48 ± 6.59 6.52 ± 3.87
CL (L ⋅ h −1) 0.12 ± 0.02 0.04 ± 0.01 0.32 ± 0.05 0.19 ± 0.02
Fr NA 325.5% NA 173.3%
Notes: (N = 6; mean ± SD). Fr = ((AUCPVP–NCTD–NP × DNCTD)/(AUCNCTD × DPVP–NCTD–NP)) × 100.
Abbreviations: SD, standard deviation; NA, not available; AUC, area under curve; t1/2(a), half-life (minutes); t1/2(β), half-life (hours); T, time; MRT, mean residence time; V, apparent 
volume of distribution; CL, clearance; Fr, relative bioavailability; D, dose.
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Figure 6 Tissue distribution of NCTD-SOL and PVP–NCTD–NPs after intravenous administration in mice (N = 6).
with distribution mostly in the liver and, secondarily, in the 
kidney. The concentration of residues in the bile was close 
to that of plasma, which was over five times greater than in 
other tissues. Liver tissue from the PVP–NCTD–NP group 
had a much higher concentration of residues (4.07 µg/mL), 
than the NCTD group; the concentrations in kidney and 
bile also increased. The targeting evaluation (Table 2), of 
targeted index (TI), targeted efficiency (Te), and relative 
targeted efficiency (RTe), showed that the trend in NCTD 
distribution in the NCTD group was from lung to heart, to 
kidney, to other tissues. The trend for the PVP–NCTD–NP 
group was from bile to kidney, to liver, to other tissues. 
These results indicate a hepatic-targeting effect of PVP–
NCTD–NPs, resulting in increased drug content in the liver, 
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Table 2 Te, RTe, and TI of NCTD and PVP–NCTD–NPs after 
intravenous administration
Tissue Te RTe TI
NCTD PVP–NCTD–NPs
Blood 30.74 41.87 0.36 2.80
Heart 14.99 2.19 −0.85 0.301
Liver 10.07 5.72 −0.43 1.168
Spleen 7.44 1.86 −0.75 0.514
Lung 22.72 3.46 −0.85 0.314
Kidney 11.72 7.52 −0.36 1.321
Bile 2.33 37.39 15.05 33.03
Notes: RTe = (TePVP–NCTD–NPs − TeNCTD) /TeNCTD × 100%.
Abbreviations: Te, targeted efficiency; Rte, relative targeted efficiency; TI, targeted 
index.
as well as increased quantity of NCTD discharged into the 
kidneys and bile.
In vivo metabolite identification  
and excretion
The full scan mass spectra of the samples collected from 
0–6 hours after oral administration of PVP–NCTD–NP were 
compared with those of blank rat urine and feces samples, to 
identify possible metabolites. These compounds were then 
analyzed using LC-MS/MS to determine their structures, 
through comparison of their retention times, changes in 
observed mass, and mass spectral patterns of product ions, 
compared against those of NCTD.28 Using this method, 
a total of seven metabolites in rat urine were identified 
as hydrolytic NCTD: hydroxy NCTD, dihydroxy NCTD, 
hydrogenant NCTD, etc. Hydrolytic NCTD and decar-
boxylated NCTD were found in rat feces. Their molecular 
ions were found at m/z 96.9, 141, 152, 167, 205, 247, and 
249. Short intervals of retention time were observed, with 
an end result at 3 minutes for short runtime experiments. 
MS/MS product ion spectra (Figure 7), obtained from the 
fragmentation of deprotonated molecular ions, were used 
to provide more precise structural identification of the 
metabolites (Figure 8).
The mass spectra of P4 showed a deprotonated molecu-
lar ion at m/z 167, which was the prototype drug. The 
molecular ion at m/z 185 (P5) was the hydrolysis product 
of the unchanged parent drug. At m/z 141 (P2) and m/z 97 
(P1), there were decreases of 44 Da and 88 Da,   respectively, 
compared with P5. The fragmentation of molecular ions con-
firmed that P2 was a product of a decarboxylation reaction 
at P5, and that P1 was generated by the loss of two carboxyl 
fragments. In investigating the fragmentation of P4 molecu-
lar ions, an intermediate compound (P3) was found, with 
an oxygen atom lost. The product ion at m/z 205 (P6) was 
generated by the addition of a neutral H2O fragment and the 
deoxidization of two hydrogen atoms at P5. The MW of the 
metabolites (P7 and P8), where fragmentations of the basic 
annulation (P1) was found, were 62 and 74 mass units greater 
than for NCTD. The major fragment ions of P7, at m/z 203 
and m/z 188, combined with ion spectra, were interpreted as 
the cleavage of carboxyl and the loss of methyl, respectively, 
followed by a neutral H2O loss to P4. The major fragment 
ions in the MS/MS spectrum of P8 showed that molecular 
ion peaks were 44, 17, 17, 44, and 28 mass units less than 
than those of P5, indicating that the fragment ions might 
correspond to dicarboxyl, dihydroxy, and carbonyl.
In contrast to a previous study,29 no glucuronide or sulfate 
conjugates of NCTD were found in the samples. This might 
be due to the different sample preparation and analytical 
methods used. This study proposes that decarboxylation and 
hydroxylation are the major metabolic pathways of NCTD 
in rats.
Residues of NCTD were highly concentrated in urine, 
relative to feces. The total residue concentrations rapidly 
increased from 0–6 hours, then slowly declined (Figure 9). 
The quantity of parent drug discharged in urine from the 
PVP–NCTD–NP group was 1.37 times greater than that 
of the NCTD group; in bile and feces it was 32.21 times 
greater. The kidney has been shown to be the main excretory 
pathway, and NPs dramatically improved the concentration 
of the parent drug, NCTD, in the urine.
A grouping experiment was carried out to investigate 
this phenomenon. The feces and bile of several mice in the 
orally-administered PVP–NCTD–NP group were analyzed 
to identify metabolites. In bile, the parent drug and other 
metabolites were found. In feces, only the parent drug was 
found. This may reveal an explanation of the phenomenon: 
metabolites were discharged first into the duodenum from 
the bile, transformed into the parent drug by intestinal flora, 
then reabsorbed by the intestinal tract, and, finally, transported 
to the liver.30 Such a process could explain the platform of 
NCTD concentration observed in pharmacokinetic studies. 
Another cause was the improved hepatic targeting of the 
PVP–NCTD–NP formulation. The survival time of rats dosed 
with PVP–NCTD–NP (20 mg/kg) reached more than 30 days. 
In contrast, survival time in the NCTD group was about 
24 hours. The urine output of the PVP–NCTD–NP group was 
approximately equal to that of normal rats, whereas that of 
the NCTD group was one-third of normal. This suggests that 
PVP–NCTD–NP could effectively lessen renal toxicity.
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Figure 7 Product ion spectra of NCTD and its metabolites in rats.
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Figure 9 Cumulative amounts of excreted NCTD in urine and feces: time curves after oral administration of NCTD and PVP–NCTD–NP to rats (N = 6).
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Figure 8 Structures of the main metabolites and their possible transformation in rats.
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Conclusion
A novel NP, based on CS and PVP K30, was synthesized and 
characterized. PVP–NCTD–NP, with stable EE and high 
DL, was demonstrated to be capable of sustained release and 
high efficiency, compared to NCTD. NPs with mean particle 
sizes of 140.03 ± 6.23 nm reduced adverse reaction in normal 
hepatic cells, by reducing passive targeting in the liver.31,32
To address the difficulty of NCTD detection, an LC-MS/
MS-based method was developed, and found to be specific, 
sensitive, and accurate for qualitative and quantitative assay. 
The pharmacokinetics of both formulations in rats were well 
fitted to a two-compartment open model. PVP–NCTD–NP 
improved the absorption of NCTD and maintained a very long 
treatment period. A tissue distribution experiment showed 
that PVP–NCTD–NP improved the hepatic targeting effect 
of NCTD. Hepatoenteral circulation was involved in the 
excretion of PVP–NCTD–NPs.
NCTD is hydrolyzed easily in body fluids to form 
hydroxyl or carboxyl metabolites. Our study suggests that 
decarboxylation and hydroxylation might be major metabolic 
pathways of NCTD in rats. Metabolite distribution was 
consistent with the results of a previous report,33 which also 
indicated that NCTD was metabolized mainly in the liver, 
passing into the kidneys before being excreted through urine. 
Our identification of seven metabolites might provide impor-
tant information regarding the bioactive forms of NCTD and 
its pharmacological mechanisms.
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